axsomelogo-468x57.jpg
Axsome Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
10 mai 2021 07h00 HE | Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
axsomelogo-468x57.jpg
Axsome Therapeutics Joins Mental Health America and other Advocacy Organizations in Raising Awareness and Providing Support for Mental Health During Mental Health Month
07 mai 2021 07h00 HE | Axsome Therapeutics, Inc.
NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) is joining Mental Health America (MHA) and other advocacy organizations in observing May is Mental Health Month,...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
30 avr. 2021 09h00 HE | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz, M.D.
29 avr. 2021 08h00 HE | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
axsomelogo-468x57.jpg
Axsome Therapeutics to Report First Quarter 2021 Financial Results on May 10, 2021
27 avr. 2021 07h00 HE | Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, May 10, 2021 at 8:00 AM Eastern Time NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder
26 avr. 2021 06h00 HE | Axsome Therapeutics, Inc.
FDA grants Priority Review and sets PDUFA action goal date of August 22, 2021 NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE
14 avr. 2021 09h00 HE | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Present at Stifel’s 3rd Annual CNS Day
24 mars 2021 08h00 HE | Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
WAVE LOGO NEW COLOR SWOOSH.jpg
Wave Life Sciences to Present at the Third Annual Stifel CNS Day
19 mars 2021 08h00 HE | Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
17 mars 2021 07h00 HE | Praxis Precision Medicines, Inc.
PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance PRAX-944 Phase 2a high dose cohort topline data expected in mid-year 2021 Innovative...